Biological E Unites with Bavarian Nordic to Combat Chikungunya in Emerging Markets

Biological E Limited has partnered with Bavarian Nordic to enhance access to the Chikungunya vaccine in low and middle-income countries. This strategic alliance involves technology transfer and possible job creation, aiming to boost vaccine supply and manufacturing capacity in these regions.

Biological E Limited has announced a strategic alliance with Bavarian Nordic to expand the reach of the Chikungunya vaccine in low and middle-income countries. This collaboration marks a significant step in fighting the disease on a broader scale.

The partnership encompasses technology transfer for manufacturing the vaccine, initially focusing on the drug product process, with potential for more comprehensive production capabilities later. The aim is to enhance supply to regions heavily impacted by Chikungunya.

BE plans to upgrade its existing facilities in Hyderabad to accommodate the new manufacturing efforts, which are projected to create up to 300 jobs. The move signifies a major boost for both the local economy and public health infrastructure.